Skip to Content

Linzagolix FDA Approval Status

FDA Approved: No
Generic name: linzagolix
Company: ObsEva SA
Treatment for: Uterine Fibroids, Endometriosis

Linzagolix is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist in development for the treatment of women with heavy menstrual bleeding associated with uterine fibroids and pain associated with endometriosis.

Development Timeline for linzagolix

Jul  6, 2020ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty┬« (linzagolix) for the Treatment of Uterine Fibroids
Jun  4, 2020ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis
Apr 22, 2020ObsEva Announces Publication of Abstracts from Phase 2b EDELWEISS Trial of Linzagolix in Endometriosis
Dec  9, 2019ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.